IMMUNOREACT 7: Regular aspirin use is associated with immune surveillance activation in colorectal cancer
Ottavia De Simoni(Istituto Oncologico Veneto), Chiara Cipollari(La Salle University), Roberta Salmaso, Giulia Becherucci(University of Padua), Ignazio Castagliuolo(University of Padua), Maurizio Zizzo(Azienda Sanitaria Unità Locale di Reggio Emilia), Ivana Cataldo(Ospedale SS. Annunziata), Giuseppe Portale(University of Southern California), Angelo Paolo Dei Tos(University of Padua), Giulia Pozza(University of Padua), Melania Scarpa(University of Padua), Daunia Verdi(ASL Roma), Cesare Ruffolo(Ca' Foncello Hospital), Astghik Stepanyan(University of Padua), Mario Godina(ASL Roma), Marco Massani(AULSS 2 Marca Trevigiana), Silvia Negro(University of Padua), Stefano Brignola(University of Padua), Valentina Chiminazzo(University of Padua), Roberto Merenda(Ospedale Civile di Venezia), Tommaso Stecca(Ca' Foncello Hospital), Giorgio Rivella(University of Padua), Antonio Scapinello(Istituto Oncologico Veneto), Mario Gruppo(Istituto Oncologico Veneto), Pierluigi Pilati(Istituto Oncologico Veneto), Marco Agostini(University of Padua), Licia Laurino(University of Padua), Chiara Romiti, Gianluca Businello(University of Padua), Antonella D’Angelo(University of Padua), Luca Saadeh(University of Padua), Federico Scognamiglio(University of Padua), Andromachi Kotsafti(Istituto Oncologico Veneto), Carlotta Ceccon(University of Padua), Luca Facci(University of Padua), Camilla Nacci(University of Padua), Isabella Mondi(Ospedale di Mirano), Giovanni Pirozzolo(Ottawa Hospital), Alfonso Recordare(Ca' Foncello Hospital), Imerio Angriman, Boris Franzato(Istituto Oncologico Veneto), Giovanni Bordignon(AULSS 2 Marca Trevigiana), Chiara Vignotto(University of Padua), Isacco Maretto(University of Padua), Vincenza Guzzardo(University of Padua), Anna Pozza(University of Padua), Francesco Marchegiani, Corrado Da Lio(Ospedale di Mirano), Silvio Guerriero
Cited by 8
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k